Hemostats Market Analysis

Global Hemostats Market Overview

The Hemostats Market Size was valued at USD 3.75 billion in 2023 and is projected to grow from USD 4.02 Billion in 2024 to USD 5.8 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.66% during the forecast period (2024 - 2032). 

Rising frequency of sports-related surgeries, continuous progression in products range, and increasing number of surgical procedures are the key market drivers enhancing the market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

November 2023, Ethicon, a Johnson & Johnson MedTech company, announced ETHIZIA had been approved as an adjunctive hemostat solution, which has been clinically proven to achieve sustained hemostasis in difficult-to-control bleeding situations. It is built with unique synthetic polymer technology, ETHIZIA™ Hemostatic Sealing Patch, which is the first and only hemostatic matrix designed to be equally active and efficacious on both sides. Designed for maximum adaptability, it can be stuffed, rolled up or unrolled into pieces or cut off as one pleases, rendering its handling quite easy during open as well as minimally invasive surgery.

In August 2023, Teleflex Incorporated, a leading global provider of medical technologies, got clearance from the U.S. Food and Drug Administration (FDA) for the QuikClot Control+ Hemostatic Device used during cardiac surgical procedures to address mild and moderate bleeding. The clearance also includes bone surface bleeding after sternotomy.

In July 2023, Baxter International Inc., a key player in surgical innovation, launched PERCLOT Absorbable Hemostatic Powder in the United States.  This novel product has been developed to provide convenient solutions for surgical procedures by facilitating effective hemostasis.

April 2023, Olympus introduced EndoClot Polysaccharide Hemostatic Spray (PHS) into Europe and Middle East and Africa (EMEA). This product is based on EndoClot Absorbable Modified Polymer (AMP) technology.

In March 2023 FDA Approves Chitosan-Based Hemostat To Control Severe Surgical Bleeding. Axio Biosolutions, based in Bangalore, has devised a superior, cheaper method of managing acute surgical bleeding.

May 2023: Olympus Europa SE & Co. KG launched three Endoclot products, two hemostatic agents and a submucosal injection agent across Europe and the Middle East and Africa (EMEA). Santa Clara, Calif.-based Endoclot Plus Inc. developed this new portfolio, which expanded its distribution with Olympus from the US to EMEA in December 2022.

Hemostats Market Trends

• Growing Prevalence of surgeries to boost market growth

The increasing number of various types of chronic diseases such as, spinal problems, cardiovascular diseases, cancer, accidents, and cases of trauma are the drivers of the hemostats market growth. This has led to the extensive surge in the surgical procedures and medical specialist for the management and treatment of various diseases across the globe. In surgical procedures blood controlling is very essential in which hemostats perform an excellent role. For Instance: as per the National Cancer Stastics, there were 1, 806,590 new cancer cases in the U.S. in 2020. According to National Center for Biotechnology Information (NCBI), approximately 60-70% of transfused red blood cells are used during surgical procedures, as bleeding at the time of surgeries one of the most complicates situation. 

To deal with the controlling bleeding has increase the demand for the product in the global market, as several surgeons choose administration of these hemostats products in surgical procedures with minimum risk factor of losing blood. These products are less prone to infections and cost effective are other factors driving the market growth of the hemostats. Hence, increase in number of surgeries is expected to boost the Hemostats Market revenue.

Further, rising sports injuries and continuous progression of new products is also enhancing the market growth during the assessed period. For instance: B.Braun invested in research and development in 2020, USD 422.4 billion. Similarly, Baxter International will invest USD 521 Billion in research and development.

Hemostats Market Segment Insights

Hemostats Product Type Insights

The market segments of Hemostats, based on product type, includes thrombin based, collagen based, tissue sealants- fibrin sealants and others. The thrombin based segment held the majority share in 2022 in respect to the Market revenue of Hemostats. This is primarily owing to the rising prevalence of surgical operations, ageing population, and increasing management for wound control, production and launch of cutting-edge and novel thrombin products and rising awareness of these products across the globe.

Hemostats Instrument Type Insights

The Hemostats Market segmentation, based on instrument type, include halstead mosquito hemostatic forceps. The halstead mosquito hemostatic forceps segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. This is due to the increasing number of surgeries in various diseases such as cardiovascular, spine surgeries, cancer, and accidents. Many healthcare professionals, including surgeons, doctors, and clinicians have an increasing preference for halstead mosquito hemostatic forceps due to power of controlling blood flow and other clamping tasks in general surgical procedures. Hence, rising applications of halstead mosquito hemostatic forceps for hemostats positively impacts the market growth.

Hemostats Application Insights

Figure 1: Hemostats Market, by Application, 2022 & 2030 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Hemostats Regional Insights

By Region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America hemostats market accounted for USD 1.6 billion in 2022 and is expected to exhibit a significant CAGR growth during the study period. This is attributed to the growing incidence of sports injuries, surgeries, as well as an ageing population across the region.

Further, the major countries studied in the market report are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: HEMOSTATS MARKET SHARE BY REGION 2022 (%)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe hemostats market accounts for the second-largest market share due to the availability of cutting-edge treatment facilities, government backing for the growth of the healthcare industry, an ageing population, and an increase in incidence of cancer, cardiovascular, and others. Further, the Germany market of hemostats held the largest market share, and the UK market of hemostats was the fastest growing market in the European region.

The Asia-Pacific hemostats Market is expected to grow at the fastest CAGR from 2022 to 2030. This is due to increased cases of cardiovascular disease, cancer, spine problems, and rising healthcare costs. Moreover, China market of hemostats held the largest market share, and the India market of hemostats was the fastest growing market in the Asia-Pacific region.

For instance, as per the International Diabetes Federation, In the South-East Asia (SEA) region, 90 billion people had diabetes in 2021. The number of diabetic patients is expected to increase in 2030 by 113 billion and 2045 by 152 billion. Increasing cases of chronic diseases, such as diabetes, obesity, and cancer, is a driving factor for market revenue growth of hemostats.

Hemostats Key Market Players & Competitive Insights

Major market players are spending a lot of money on R&D to increase their product lines, which will help the market growth of hemostats. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the hemostats industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

One of the primary business strategies adopted by manufacturers in the global hemostats industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, hemostats industry has provided medicine with some of the most significant benefits. The hemostats market major player such as CR Bard Inc. (US), B. Braun Melsungen AG (Germany), Baxter International Inc. (US), Integra LifeSciences (US), Marine Polymer Technologies Inc. (US), Teleflex (US), Ethicon Inc. (US), Pfizer Inc. (US), Z-Medica LLC (US), Gelita Medical GmbH, and others are working to expand the market demand by investing in research and development activities.

Baxter International Inc. (US) is focused on the crucial junction where the life-saving and life-sustaining goods meet the healthcare workers and carers who make it all possible. With a wide range of solutions, we can now assist more patients at every stage of their journey and enable medical professionals to provide treatment that is more intelligent and individualized. Together, we are reshaping healthcare with audacious ideas that will enable us to fulfill our common commitment to enhancing care for everyone. For instance: In 2020, Baxter International Inc. (US) announced 510(k) clearance from the US FDA for Peri-strips Dry with Veritas Collagen Matrix product with Secure Grip. The Matrix product helps in mitigating bleeding at the time of bariatric surgeries and other surgical procedures.

Ethicon Inc. is a subsidiary company of Johnson & Johnson.  According to Ethicon Inc. patient care is never one-size-fits-all. Every person has different requirements, so they innovate accordingly. Company produces surgical and interventional solutions that center on the exclusive journey of each and every patient, and support to discover more efficient, innovative pathways to healing. Company’s mission is to solve for the individual has led to an innovative 3D mapping technology, an energy sealing device, visible patient, ENSEAL® X1 Tissue Sealers. For Instance: Ethicon launched Surgical Powder Absorable Hemostat in Australia, New Zealand, and Thailand.

Key Companies in the market of Hemostats includes

• CR Bard Inc. (US)


• Braun Melsungen AG (Germany)


• Baxter International Inc. (US)


• Integra LifeSciences (US)


• Marine Polymer Technologies Inc. (US)


• Teleflex (US)


• Ethicon Inc. (US)


• Pfizer Inc. (US)


• Z-Medica LLC (US)


• Gelita Medical GmbH, among others

Hemostats Industry Developments

2021 Baxter acquired PerClot Polysaccharide Hemostatic system to expand advanced surgery portfolio.

2020 Teleflex acquired Z-Medica, LLC (US), a private company that produces and sells hemostatic products marketed under the QuikClot Combat Gauze and QuickClot Control+ brand names to expand its product portfolio.

December 2019 Ethicon Launched VISTASEAL Fibrin Sealant for the management or to control the blood during surgical procedures.                                                           

Hemostats Market Segmentation

Hemostats Product Type Outlook

• Thrombin Based


• Collagen Based


• Tissue Sealants- Fibrin Sealants


• Others

Hemostats Instrument Type Outlook

• Halstead Mosquito Hemostatic Forceps

Hemostats Application Outlook

• Gynecology


• Neurology


• Cardiovascular

Hemostats Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America